Table 1.
Summary of the studies, which have identified the elevated ASPH expression in human tumor tissues
| Study | Tumor tissues | Positive cases of studied samples (n/n) | Detection method | Antibody (recognized region of ASPH protein) |
|---|---|---|---|---|
| Lavaissiere et al., [3] | Hepatocellular | 4/10 | IHC | FB-50 Ab (N-terminus) |
| Cholangiocarcinoma | 20/20 | |||
| Breast | 4/4 | |||
| Colon | 6/10 | |||
| Palumbo et al., [35] | Pancreatic adenocarcinoma | 19/19 | IHC | FB-50 Ab (N-terminus) |
| Sepe et al., [30] | Primitive neuroectodermal (medulloblastoma, neuroblastoma) | 28/28 | IHC | FB-50 Ab (N-terminus) |
| Maeda et al., [36] | Cholangiocarcinoma | 42/50 | IHC | FB-50 Ab (N-terminus) |
| Cantarini et al., [37] | Hepatocellular | 13/15 | IHC | FB-50 Ab (N-terminus) or 15C7 Ab (catalytic domain) |
| 13/15 (7.5-fold higher level of mRNA compared to normal tissue) | RT-qPCR | |||
| Monte et al., [38] | Hepatocellular | 8/8 | IHC | FB-50 Ab (N-terminus) |
| 8/8 (7-fold higher level of mRNA compared to normal tissue) | RT-qPCR | |||
| Yang et al., [39] | 19 types of tumor tissuesa | 94/104 | IHC | mAb G3 hybridoma |
| Wang et al., [40] | Hepatocellular | 150/233 | IHC | Polyclonal |
| Dong et al., [41] | Pancreatic cancer | 101/104 | IHC | FB-50 mAb (N-terminus) |
| Tang et al., [32] | Hepatocellular | 71/140 | RT-qPCR | |
| Lin et al., [42] | Breast | 127/141 | IHC | FB-50 Ab (N-terminus) |
| Ogawa et al., [43] | Pancreatic ductal adenocarcinoma | 162/166 | IHC | FB-50 Ab (N-terminus) |
aLiver, kidney, breast, cervical, ovarian, Fallopian tube, laryngeal, lung, thyroid, pancreatic, thymic, prostate, bladder, esophagus, gastric, gall bladder, colon, and rectum cancer and cholangiocarcinoma